Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trial

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trialПодробнее

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemiaПодробнее

Phase II study of inotuzumab ozogamicin in MRD+ B-ALLПодробнее

Inotuzumab ozogamicin for MRD-positive B-ALLПодробнее

The addition of inotuzumab ozogamicin to hyper-CVAD + blinatumomab in patients with B-ALLПодробнее

Novel ALL treatment strategies: inotuzumab ozogamicinПодробнее

Emerging novel approaches for ALL: inotuzumab ozogamicinПодробнее

Inotuzumab ozogamicin for treating pediatric R/R ALLПодробнее

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALLПодробнее

Update on the INO-VATE trial: inotuzumab vs chemotherapy for ALLПодробнее

Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)Подробнее

Clinical trials in acute lymphoblastic leukemiaПодробнее

When to Use Inotuzumab Ozogamicin for Adult ALLПодробнее

The future of inotuzumab therapy for ALLПодробнее

Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALLПодробнее

Optimizing conventional chemotherapy in ALLПодробнее

5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclaxПодробнее

What is the role of inotuzumab ozogamicin in ALLПодробнее

The evolving role of inotuzumab ozogamicin in the treatment of pediatric & older patients with ALLПодробнее

What’s next for inotuzumab ozogamicin in ALL?Подробнее